We are live on ! Find out more
TA

Tamarack Advisers Portfolio holdings

AUM $2.12M
1-Year Est. Return 58.09%
This Fund
S&P 500
This Quarter Est. Return
+42.22%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$438M
AUM Growth
+$53.9M
Cap. Flow
+$17.2M
Cap. Flow %
3.94%
Top 10 Hldgs %
64.1%
Holding
37
New
6
Increased
12
Reduced
11
Closed
8

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$17M
2
PHR icon
Phreesia
PHR
+$12.7M
3
HOLX
Hologic
HOLX
+$9.71M
4
VTRS icon
Viatris
VTRS
+$8.37M
5
DGX icon
Quest Diagnostics
DGX
+$7.3M

Top Sells

Rank Stock Value
1
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$11.2M
2
CMD
Cantel Medical Corporation
CMD
+$10.1M
3
HMSY
HMS Holdings Corp.
HMSY
+$7.75M
4
PCRX icon
Pacira BioSciences
PCRX
+$6.48M
5
MDRX
Veradigm Inc. Common Stock
MDRX
+$6.05M

Sector Composition

Rank Sector Weight
1 Healthcare 95.54%
2 Industrials 4.25%
3 Miscellaneous 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDT icon
1
Medtronic
MDT
$120B
$43.8M 10.02%
385,000
-15,000
-4% -$1.65M
BIO icon
2
Bio-Rad Laboratories Class A
BIO
$10.3B
$36.7M 8.38%
100,000
-15,000
-13% -$5.29M
MDRX
3
DELISTED
Veradigm Inc. Common Stock
MDRX
$35.1M 8.03%
3,650,000
-575,000
-14% -$6.05M
ATRC icon
4
AtriCure
ATRC
$2.62B
$27.9M 6.38%
860,000
+10,000
+1% +$285K
PCRX icon
5
Pacira BioSciences
PCRX
$1.05B
$27.8M 6.35%
622,500
-152,500
-20% -$6.48M
DGX icon
6
Quest Diagnostics
DGX
$26.2B
$25.7M 5.88%
245,000
+70,000
+40% +$7.3M
HOLX
7
DELISTED
Hologic
HOLX
$24.6M 5.63%
475,000
+195,000
+70% +$9.71M
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$21.6M 4.93%
2,650,000
-350,000
-12% -$1.25M
ZBH icon
9
Zimmer Biomet
ZBH
$18.7B
$18.6M 4.25%
128,750
-36,050
-22% -$4.98M
SRCL
10
DELISTED
Stericycle Inc
SRCL
$18.6M 4.25%
300,000
-50,000
-14% -$2.96M
JNJ icon
11
Johnson & Johnson
JNJ
$663B
$18M 4.12%
+125,000
New +$17M
PHR icon
12
Phreesia
PHR
$679M
$17.5M 4.01%
660,000
+460,000
+230% +$12.7M
PTLA
13
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$14.3M 3.26%
595,000
-405,000
-41% -$11.2M
ITGR icon
14
Integer Holdings
ITGR
$4.3B
$13.4M 3.05%
165,000
+50,000
+43% +$3.82M
UTHR icon
15
United Therapeutics
UTHR
$20.9B
$13.1M 2.99%
151,400
+76,400
+102% +$6.72M
ICUI icon
16
ICU Medical
ICUI
$4.19B
$13M 2.97%
70,000
+35,000
+100% +$6.02M
LNTH icon
17
Lantheus
LNTH
$6.59B
$12.5M 2.85%
650,000
-100,000
-13% -$2.02M
RIGL icon
18
Rigel Pharmaceuticals
RIGL
$909M
$11.8M 2.69%
575,000
+27,500
+5% +$566K
VTRS icon
19
Viatris
VTRS
$19.4B
$9.09M 2.08%
+450,000
New +$8.37M
OPTN
20
DELISTED
OptiNose
OPTN
$8.57M 1.96%
70,000
+25,000
+56% +$3.24M
RDNT icon
21
RadNet
RDNT
$5.8B
$8.27M 1.89%
400,000
+75,000
+23% +$1.29M
STRM
22
DELISTED
Streamline Health Solutions
STRM
$5.99M 1.37%
287,059
+147,059
+105% +$2.71M
INGN icon
23
Inogen
INGN
$144M
$4.98M 1.14%
+75,000
New +$4.7M
NVRO
24
DELISTED
NEVRO CORP.
NVRO
$4.72M 1.08%
40,000
-12,864
-24% -$1.27M
CORV
25
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$1.02M 0.23%
2,500,000
-2,000,000
-44% -$3.32M
1
2

Similar funds

SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
LBC
Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
STC
Sarah T. Connolly $1.11M AUM 24.13% 1-Year Est. Return
GC
Gilfoyle & Co San Francisco, California $671K AUM
DU
Delphia (USA) Toronto, Ontario, Canada $445K AUM 28.82% 1-Year Est. Return

Tamarack Advisers's Q4 2019 Portfolio in Review

As of Q4 2019, Tamarack Advisers held 37 positions worth $438M, up 14% from $384M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Tamarack Advisers deployed $17.2M of net new capital in Q4 2019, opening 6 new positions and adding to 12 existing holdings. Its largest new stake was Johnson & Johnson: 125,000 shares worth $18M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 93% a quarter earlier, followed by Industrials and Miscellaneous.

On the sell side, the largest reduction was Portola Pharmaceuticals, Inc., an estimated $11.2M trimmed.

  • Tamarack Advisers's largest Q4 2019 buy was Johnson & Johnson: 125,000 shares worth $18M.
  • Tamarack Advisers added most to Phreesia in Q4 2019, an estimated $12.7M increase.
  • Tamarack Advisers's biggest Q4 2019 reduction was Portola Pharmaceuticals, Inc., cutting an estimated $11.2M.
  • Tamarack Advisers fully exited Cantel Medical Corporation in Q4 2019, selling an estimated $10.1M.
  • Tamarack Advisers's ten largest holdings make up 64% of its $438M portfolio in Q4 2019.
  • Tamarack Advisers opened 6 new positions and closed 8 in Q4 2019.
  • Tamarack Advisers's portfolio value rose 14% quarter-over-quarter to $438M.

Based on Tamarack Advisers's 13F filing for Q4 2019, filed 11 Feb 2020.